We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Patient Safety Improved with Reduction in Blood Transfusions

By LabMedica International staff writers
Posted on 28 Oct 2010
Print article
Blood transfusions save lives, but they also carry risks. Studies during the past 10 years have found that transfusions make patients more susceptible to infections and increase the risks of poor outcomes such as longer hospital stays, cancer recurrences, and multi-organ system failures.

Transfusions of red blood cells, platelets, plasma, and other blood products were approved decades ago without randomized controlled clinical trials to establish optimal uses. Consequently, doctors sometimes order more transfusions than necessary said Phillip J. DeChristopher, M.D., Ph.D., professor in the Department of Pathology at Loyola University Chicago Stritch School of Medicine and medical director of transfusion medicine, blood bank, and apheresis.
He noted that the amount of plasma transfused per patient in the United States is two to three times higher than the amounts transfused in Canada and Europe.

In a Loyola University study, a new initiative was launched for blood utilization as part of its Blood Management Program. The program implemented blood-use protocols that included evidence-based indications, educational programs for doctors and nurses, and oversight of the Blood Utilization Review Committee.

The study demonstrated how the hospital improved patient safety and cut costs by reducing the number of blood transfusions. These results were reported at the recent annual meeting of the College of American Pathologists, which took place from September 26–29, 2010, in Chicago (IL, USA).

Results of a small clinical trial reported at the American Society of Anesthesiologists annual meeting in San Diego (CA, USA) on October 18, 2010, demonstrated how a new noninvasive continuous blood monitor could reduce the number of blood transfusions given during surgery.

Developed by Masimo (Irvine, CA, USA) the Radical-7 pulse oximeter equipped with continuous hemoglobin monitoring sensors helped anesthesiologists to know whether a patient's blood count is critical without having to wait for lab reports. The results of the trial showed that the real-time blood-monitoring tool could cut the number of transfusions by almost 86%.

Making sure blood transfusions are performed only when necessary would help lower complications from transfusions. Although they save lives, transfusions also carry risks of serious immune reactions. Blood management will also help relieve chronic shortages in the blood supply, especially during summers and holiday seasons when donations drop.

Related Links:

Masimo




Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.